NICE
Cost of NHS medicines rises
November 14, 2014Sales and Marketing HSCIC, NHS, NICE, PPRS, drugs, hospitals, spend
Hospitals in England are taking an increasing share of the NHS’s bill for drugs approved by NICE, according to a …
Charity ‘deeply concerned’ on CDF changes
November 13, 2014Research and Development, Sales and Marketing CDF, Cancer, NHS, NICE, breakthrough breast cancer, palframan
A leading cancer charity has warned that a number of key drugs are at risk of being withdrawn from patients …
Sir Michael Rawlins appointed chair of MHRA
November 4, 2014Manufacturing and Production, Medical Communications, Sales and Marketing MHRA, NHS, NICE, gordon duff, michael rawlins
The Medicines and Healthcare Products Regulatory Agency (MHRA) has confirmed that former NICE head Sir Michael Rawlins is to serve …
NICE backs GSK’s leukaemia drug Arzerra following price cut
November 4, 2014Sales and Marketing Arzerra, CLL, GSK, NHS, NICE, leukaemia
NICE has recommended that GlaxoSmithKline’s Arzerra be prescribed under the NHS for patients with chronic lymphocytic leukaemia (CLL), after a …
UK doctors are ignoring statin guidance
November 3, 2014Sales and Marketing British Medical Association, GPs, NHS, NICE, Royal College of GPs, Royal College of Physicians, statins
A survey of UK doctors has found that many are refusing to apply NICE advice to offer statin therapy to …
NICE recommends new indication for troubled Pradaxa
October 31, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, dabigatran, ingelheim, warfarin
NICE has recommended Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa for treating and preventing potentially-fatal blood clots in the legs …
Cancer Drugs Fund ‘papering over the cracks of a bigger issue’
October 29, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, Kadcyla, NICE, breast cancer, reform
Breakthrough Breast Cancer has raised concerns to the government this week over the ever-increasing price of new oncology medicines. Over …
NICE under increased pressure over conflicts of interest
October 22, 2014Sales and Marketing GPs, NHS, NICE, UK, baker, conflict, mccoll, wollaston
A group of influential doctors is calling on the government to tighten up NICE’s conflicts of interests policy. In a …
Novartis cancer drug beating path to NHS
October 17, 2014Sales and Marketing GIST, Glivec, NHS, NICE, imatinib, uturn
NICE has issued final draft guidance recommending Novartis’s Glivec for up to three years in people who have had a …
NICE not recommending Dendreon cancer vaccine
October 16, 2014Sales and Marketing Dendreon, NHS, NICE, Provenge, sipuleucel-T, therapeutic cancer vaccine
NICE has issued preliminary draft guidance not recommending Dendreon’s therapeutic cancer vaccine Provenge for prostate cancer in people whose disease …
NICE releases ‘person-centred’ medicines optimisation guidelines
October 14, 2014Research and Development, Sales and Marketing ABPI, NHS, NICE, UK, WHO, Whitehead
NICE has recently released the draft of its first guidance on medicines optimisation that it hopes will be more person-centered …
Public opinion divided over UK drugs spend
October 7, 2014Medical Communications, Research and Development, Sales and Marketing ABPI, CDF, NHS, NICE, PPRS, UK, coalition, drugs spending, government
A new survey conducted for the ABPI shows that public opinion on whether the UK spends enough money on medicines …
Roche falls foul of NICE rules, again
October 3, 2014Medical Communications, Sales and Marketing CLL, Gazyvaro, NICE, Roche, blood cancer, oncology
Uncertainties in the data and high cost have seen NICE make an initial rejection of Roche’s new blood cancer drug …
Charities must be clear about pharma funding
October 1, 2014Medical Communications, Sales and Marketing ABPI, NICE, Sativex, charity, funding, mind, pharma
There is growing need for transparency around patient groups and health charities as they are widely perceived to be independent …
GSK melanoma drug sees quick NICE nod
September 18, 2014Sales and Marketing Cancer, GSK, NICE, Tafinlar, Yervoy, dabrafenib, melanoma, skin cancer
NICE is recommending GlaxoSmithKline’s new melanoma treatment Tafinlar (dabrafenib) after the firm offered a discount for its medicine. In final …
Latest content
FibroFind appoints Lee Borthwick as CEO
